Key Highlights

  • Kairos has signed, but not closed, term sheets to acquire two lung-cancer assets, CL-273 and CL-741, from Celyn Therapeutics; only the CL-273 term sheet discloses consideration in an SEC filing.
  • Lead candidate ENV-105 (carotuximab) showed a clean interim safety profile in 13 patients in a Phase 1 lung-cancer combination trial and remains in an ongoing Phase 2 prostate-cancer trial.
  • As of March 31, 2026, Kairos held $3.675 million in cash against a widening net loss, and its filings disclose substantial doubt about its ability to continue as a going concern.
  • CL-741 has never had its own material-agreement filing disclosing terms or a closing timeline; it appears only in the February and June 2026 press releases and should be treated as an announced intention, not a priced transaction.

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) has spent 2026 stacking oncology assets onto its clinical pipeline while advancing its lead antibody, ENV-105, through two cancer trials. Two proposed acquisitions from Celyn Therapeutics remain unclosed term-sheet transactions, not completed deals, and the company continues to disclose going-concern doubt even as it lines up several milestones for the rest of the year.

Why KAPA Is Back on Investors' Radar

Kairos Pharma has been a frequent name in small-cap biotech news flow through the first half of 2026, driven by a mid-year shareholder letter, two proposed asset acquisitions and fresh clinical data on its lead antibody. In a June 4, 2026 letter to shareholders furnished to the SEC, chief executive John Yu, M.D., recapped first-half activity and previewed milestones expected before year-end, including new prostate-trial sites and a lung-cancer safety readout.

That promotional letter is only a starting point. Shareholder letters build enthusiasm, and several claims in it, including the characterization of two pending deals as acquisitions, need checking against the SEC filings that carry the actual terms. Kairos is a clinical-stage biopharmaceutical company listed on NYSE American under ticker KAPA, confirmed in its recent 10-Q and 8-K cover pages (EDGAR CIK 0001962011).

Inside the Business: A Drug-Resistance Platform Built at Cedars-Sinai

Kairos was incorporated in California in 2013 as NanoGB13, Inc., renamed Kairos Pharma in 2016, and converted into a Delaware corporation in 2023, per its most recent Form 10-Q. The company licenses intellectual property from Cedars-Sinai Medical Center and focuses on reversing drug resistance and immune suppression in cancer. Its lead candidate, ENV-105 (carotuximab), targets CD105 (endoglin), a protein it says becomes elevated when tumors develop resistance to standard therapies.

ENV-105 is being tested in a Phase 2 trial in castration-resistant prostate cancer and a Phase 1 trial combining it with AstraZeneca's osimertinib (Tagrisso) in EGFR-mutated lung cancer, per the July 15, 2026 release. The pipeline also references earlier-stage candidates KROS-102, KROS-201 and ENV-205.

Kairos completed its IPO on September 17, 2024, selling 1,550,000 shares at $4.00 apiece for gross proceeds of $6.2 million. Per the company's IPO closing release, KAPA shares began trading on NYSE American that week and have stayed there since.

Catalyst Analysis: What Kairos Pharma's Pending Deals Actually Say

The shareholder letter's central claim is that Kairos is expanding through acquisitions. The SEC record is more conditional. On February 26, 2026, Kairos announced a term sheet with Celyn Therapeutics, a private biotech backed by OrbiMed and Torrey Pines Investment, to acquire worldwide rights to two NSCLC assets: CL-273, a pre-IND pan-EGFR inhibitor, and CL-741, a Phase 1-ready c-MET kinase inhibitor.

Only CL-273 has been documented with specific consideration. In a binding term sheet dated March 2, 2026, Kairos agreed to acquire 100% of worldwide rights to CL-273 for shares equal to 16.5% of its fully diluted capital stock, a $15 million milestone at FDA approval, and a 2% U.S. net-sales royalty. Closing still needs due diligence, a definitive agreement and shareholder and NYSE American approval; as of the May 13, 2026 10-Q, it had not closed.

CL-741 has never had its own material-agreement filing disclosing terms or a closing timeline; it appears only in the February and June 2026 press releases and should be treated as an announced intention, not a priced transaction. Separately, on July 22, 2026, Kairos disclosed a research agreement under which Bayer will supply radiopharmaceutical XOFIGO for a Kairos-run study combining it with ENV-105 in bone-metastatic prostate cancer; the filing shows no cash changing hands, with Kairos solely financing the study.

Latest Financial and Operational Performance

Kairos generates no product revenue. For the quarter ended March 31, 2026, it reported a net loss of $1.654 million, up from $1.262 million a year earlier, on R&D expense of $684,000 (up from $493,000) and G&A expense of $1.006 million (up from $773,000), reflecting higher public-company costs. The July 15, 2026 release disclosed interim Phase 1 safety data showing zero Grade 3-or-higher toxicities among 13 patients on ENV-105 plus osimertinib, and the company has said its Phase 2 prostate trial has shown median progression-free survival exceeding 13 months: a company-reported figure from an ongoing trial.

Cash, Debt and the Going-Concern Question

Kairos ended the quarter with $3.675 million in cash, down from $4.491 million at year-end 2025, against an accumulated deficit of $15.916 million. Shares outstanding rose to 21,411,198 by May 11, 2026, from 13,736,597 at end-2024, reflecting dilution from at-the-market sales, warrants and prior placements. It has an at-the-market facility with H.C. Wainwright, which raised $385,000 gross in the quarter, plus an undrawn $30 million equity line and a $75 million shelf filed in January 2026.

The 10-Q states that recurring losses "raise substantial doubt about the Company's ability to continue as a going concern," a view its auditor also reached on the 2025 annual statements. Management adds that existing cash may not fund planned operations for the next 12 months from the filing date. The letter's claim of "more than $8 million dollars already in non-dilutive funding" is a company statement not separately itemized in the filings reviewed here.

Growth Opportunities and Upcoming Milestones

Kairos has flagged catalysts before year-end: initiating a Phase 1 study of CL-741 if that acquisition proceeds, adding sites to the Phase 2 prostate trial, and reporting safety and efficacy data from the Phase 1 lung-cancer trial, targeted for the third quarter of 2026. The Bayer tie-up adds a bone-metastasis angle without committing Bayer's balance sheet. If CL-273 closes as disclosed, the 16.5% equity issuance would meaningfully dilute shareholders.

Material Risks Specific to Kairos Pharma

The most immediate risk is financial: going-concern language, a thin cash balance and a track record of dilutive financings. Both Celyn deals remain conditional: CL-273 could fail diligence or approval, and CL-741's terms are not yet public. Clinical data so far come from small, company-sponsored trials without independent confirmation, and CL-273 has not entered human trials. Kairos also disclosed a material weakness in internal controls tied to segregation of duties, unremediated as of March 31, 2026.

Outlook

On the upside, Kairos has several 2026 shots on goal: a possible CL-273 closing, an ENV-105 lung-cancer update, added prostate-trial sites and the Bayer tie-up. In a base case, the company keeps running existing trials on current funding while working to close the Celyn deals, likely needing further capital raises. In a downside case, the transactions fail to close favorably, readouts disappoint, and going-concern pressure forces more dilutive financing. This article does not predict where KAPA shares will trade and is not investment advice.

Conclusion

Kairos Pharma, Ltd. (KAPA) has genuine near-term catalysts: interim ENV-105 safety data, a Bayer research collaboration and a partly documented pipeline deal with Celyn Therapeutics. But the shareholder letter compresses two separate, unclosed transactions into an "acquisitions" narrative, and SEC filings carry going-concern doubt alongside a thin cash cushion. Investors weighing KAPA should separate the promotional framing from what its 8-Ks and 10-Q confirm.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.